(99m)Tc-labeling of ciprofloxacin and nitrofuryl thiosemicarbazone using fac-[(99m)Tc(CO)3(H2O)3] core: evaluation of their efficacy as infection imaging agents

The aim of this study was to radiolabel ciprofloxacin (Cip) and nitrofuryl thiosemicarbazone (NFT) with the fac-[(99m)Tc(CO)(3)(H(2)O)(3)](+) core and to evaluate the ability of the radiopharmaceuticals as tracers in detecting sites of infection. Cip and NFT were radiolabeled with the fac-[(99m)Tc(CO)(3)(H(2)O)(3)](+) core and characterized by RHPLC. The stabilities of the preparations were evaluated in saline and rat serum. In vitro binding studies of the radiopharmaceuticals with S. aureus were performed. Biodistribution studies were conducted at different time points after injecting (i.v.) the radiopharmaceuticals in rats (intramuscularly infected with S. aureus) as well as in rats with sterile inflammation. To assess the infection targeting capacity of (99m)Tc-tricarbonyl ciprofloxacin and nitrofuryl thiosemicarbazone, (99m)Tc(v)O-Cip and (99m)Tc(v)O-NFT were used as control. Scintigraphic imaging studies of tricarbonyl compounds and (99m)Tc(v)O-Cip were performed at 4 h after injection. The radiochemical purities of (99m)Tc(CO)(3)-Cip and (99m)Tc(CO)(3)-NFT were between 97-98% as determined by thin layer chromatography (TLRC) and RHPLC; no further purification is necessary before injection. The radiopharmaceuticals exhibited substantial stability when incubated in isotonic saline and serum up to 24 h. Biodistribution studies showed maximum uptake in the infected rat thigh muscle at 4 h post injection and washing out at slower rate from the infected site than the oxo technetium chelate. The mean ratios of uptake in infected/non-infected thighs were 3.87:1, 3.41:1 and 3.17:1 for (99m)Tc(CO)(3)-Cip, (99m)Tc(CO)(3)-NFT and (99m)Tc(v)O-Cip respectively. During scintigraphic studies, infection sites appeared quite distinctly with (99m)Tc(CO)(3)-Cip and (99m)Tc(CO)(3)-NFT, comparable to the behaviour with (99m)Tc(v)O-Cip. These results encouraged us for further development of infection imaging radiopharmaceuticals based on the (99m)Tc-tricarbonyl core.

Separation of pertechnetate from molybdate by anion-exchange chromatography: Recovery of99mTc from (n, γ)99Mo and suitability for use in central radiopharmacy (CRPh)

A novel method for the recovery of99mTcO4−from (n, γ)99Mo using conventional anion-exchange chromatography over Dowex-1 × 8 column, followed by elution and subsequent novel purification over AgCl-alumina column is reported.99MoO42−solution (7 − 14 GBq/mg) in NaOH was passed down a Dowex-1 × 8 column (6 − 7 × 2 mm), collected and preserved for reuse on the subsequent days.99mTcO4−preferentially retained on the Dowex-1 column, was recovered quantitatively by elution with 4 ml of 4 M HNO3or 4 ml 0.2 M HClO4or 6 ml of 0.2 M NaI solution. Further purification to deliver99mTcO4−in a physiological vehicle has been achieved. Use of NaI eluent and post elution purification over a bed of 1 g AgCl + 1 g alumina developed has been adapted in preference to the other two eluents. The overall yield of99mTcO4−was 75%−85% and the quality features of99mTcO4−were compatible to radiopharmaceutical use. The method has applicability for decontamination of99gTc from spent99Mo waste solution and recovery of99gTc for research use. The procedure should also be equally applicable for recovery of188ReO4−from188WO42−in a radioisotope laboratory.

Technetium-99m DTPA dimethyl ester: a renal function imaging agent. Comparative studies in animals with technetium-99m mercaptoacetyl triglycine and 131I-ortho-iodohippurate

The dimethyl ester of diethylene triamine penta-acetic acid (DMDTPA) (I) can be easily and efficiently labelled with 99mTc. This method can be readily adapted for kit formulations to produce a highly stable and very pure chelate, as shown by paper electrophoresis and reverse-phase high performance liquid chromatography experiments. In mice, this chelate was excreted unchanged in the urine, and the amount of renal excretion was much higher than that of 99mTc-DTPA and comparable with that of 99mTc-mercaptoacetyl triglycine (99mTc-MAG(3)) at two different time points. The renal excretion of co-injected 131I-ortho-iodohippurate (131I-OIH), however, was significantly greater than that of the 99mTc chelates. The renal clearance values of 99mTc-DMDTPA and 99mTc-MAG(3) were also similar and exceeded the corresponding value for 99mTc-DTPA, but were only half that of the 131I-OIH value in the rat. The renograms for 99mTc-DMDTPA and 99mTc-MAG(3) showed overall similarity in a dog model. The diethyl ester (III) and monoethyl ester (II) of DTPA, after labelling with 99mTc, produced the same chelate, as shown by analytical results and biological data, indicating that one of the ester groups in the DTPA diester is dealkylated during the chelation procedure. To confirm this, two more ligands, diethylene triamine 1,4,7,7-tetra-acetic acid (IV) and diethylene triamine 1,4,7-triacetic acid (V), were synthesized, resembling DTPA monoalkyl ester (II) and dialkyl ester (I, III), respectively, in the arrangement of the donor atoms. Ligand IV but not ligand V, on 99mTc chelation, can generate the specific pharmacophore for renal tubular transport that is also present in the ester chelates 99mTc-I, 99mTc-II and 99mTc-III, as shown by their decreased renal excretion in mice pretreated with a renal tubular transport inhibitor such as probenecid.

Stabilisation of [131I]meta-iodobenzylguanidine at room temperature as organic extract in ethyl acetate/chloroform

A method of purification of [131I]mIBG (diagnostic dose) by solvent extraction and possibility of its stabilisation by storage in ethyl acetate and chloroform at up to 40 degrees C for not less than 14 days is described. In order to further enhance the utility of this finding, the organic extract was dispensed into vials and dried. Vials containing such dried residue of [131I]mIBG stored at up to 40 degrees C was also found to be stable for at least 10 days. The final product reconstituted as aqueous solution resulted in 90% recovery with 99% radiochemical purity as assessed by previously reported methods, as well as a relatively more rapid paper chromatography method standardised by us. These interesting findings promise simpler and economic packaging besides transport of diagnostic doses of [131I]mIBG.

A paper chromatographic technique for quantitative evaluation of hydrolysed and ionic components in 201Tl radiopharmaceuticals

A reported paper chromatographic technique has been extended to delineate the hydrolysed components in 201Tl radiopharmaceuticals for the determination of radiochemical purity. Detailed radiochemical purity analysis of 201TlCl has been demonstrated using mini paper chromatographic systems. The technique is also useful in evaluation of the radiochemical purity of 67Ga and 111In radiopharmaceuticals.

Technetium-99m radiolabeled ouabagenin-cysteine conjugate: biological evaluation in animal models

Two ouabagenin-cysteine conjugates were synthesized by condensing 3-beta monochloroacetyl and 3-beta, 11-alpha dichloroacetyl ouabagenin with cysteine. The resulting ligands were radiolabeled with technetium-99m (99mTc) to furnish a single homogenous 99mTc chelate in each case with good stability. The animal experiments with these 99mTc-labeled conjugates established the superiority of guinea pig over rat and rabbit as an animal model, as previously observed for other tritiated or radioidinated cardiac glycosides or aglycones. In biodistribution experiments in guinea pig, these 99mTc chelates showed a favorable heart to liver (and other nontarget organ) uptake ratio, comparable to that of recently reported 125I-digoxigenin iodohistamine-3-oxime. The low heart to blood ratio in animal experiments with ouabagenin derivatives could be attributed to the absence of 3-beta sugar residues in these molecules, which is in agreement with the previous observation reported in connection with radioiodinated digoxin and digoxigenin derivatives.

Iodoacetylated ouabagenins: their syntheses, spectroscopic characterizations, and stability studies

Ouabain shows high binding ability to myocardial Na+,K(+)-ATPase and, therefore, a suitably radiolabeled derivative of this compound may find use in myocardial imaging. In this pilot experiment we report the preparation of several chloroacetylated and iodoacetylated ouabagenins. These intermediates may possess the potential for conversion to 99mTc-labeled tracer by a reported procedure with which the imaging of myocardial Na+,K(+)-ATPase may be possible. Appropriate analytical and spectroscopic data for these intermediates are reported for the first time. To determine the stability of the iodoacetylated ouabagenins, corresponding 131I derivatives were synthesized which showed sufficient stability for incorporating a suitable radiometal-binding chelating moiety to these steroid molecules.

99Tcm-cystine, a renal function and imaging agent: a comparative study in dog with 131I-hippurate and 99Tcm-glucoheptonate to evaluate its functional and imaging characteristics

99Tcm-cystine, which has been proposed as a renal radiopharmaceutical for evaluating renal morphology and function in a single experiment, is compared with 131I-orthoiodohippurate (OIH) with respect to its renal clearance and extraction parameters and with 99Tcm-glucoheptonate (GHA) regarding its imaging characteristics. In spite of its comparable renal accumulation with 131I-OIH, its clearance (10.1 +/- 1.0 ml min-1 kg-1) was lower than that of 131I-OIH (21.5 +/- 0.9 ml min-1 kg-1) but was higher than that of 125I-iothalamate (5.4 +/- 0.6 ml min-1 kg-1). Extraction efficiencies of 99Tcm-cystine, 131I-OIH and 125I-iothalamate were 39 +/- 5, 64 +/- 4 and 27 +/- 3, respectively. The glomerular filtration components of 99Tcm-cystine and 131I-OIH were 26 and 16% of their respective clearances. In probenecid-treated animals the clearance of both agents was affected to a similar extent and fell to half of their respective control values, whereas tubular secretory components were found to be 19 and 31% of the controls. The kidney images obtained with 99Tcm-cystine were superior to those obtained with 99Tcm-GHA at different time points. Therefore, considering both renal function and imaging properties of 99Tcm-cystine it appears that this radiopharmaceutical offers some definite advantages over the currently available renal agents and commands further study.